

Fig. S11. Cocktail of ASK-related antibodies substantially blocks SARS-CoV-2 entry.

a and b, KREMEN1, ASGR1 or ACE2 expressed HEK293E cells were incubated with SARS-CoV-2 S-ECD-hFc (10μg/ml final concentration) in the presence of anti-ASGR1 S23 antibody (**a**) or anti-KREMEN1 K33 antibody (**b**). S-ECD binding relative to control antibody treatment were measured by flow cytometry (n=2). **c**, S23 and K33 (5μg/mL final concentration) do not affect SARS-CoV-2 S-driven entry into ACE2 dependent NCI-H1650 and Huh-7 cells. Luciferase activity was measured 48 hr post-in fection (n=3). **d,** NCI-H661 and NCI-H1944 were infected with S-pseudotyped SARS-CoV-2 in the presence of Ab-414 and K33 (5μg/mL final concentration) separately or combined. Luciferase activities were measured 60 hr post-infection (mean ± SEM, n=3). **e**, Immuno-fluorescence staining showed the expression of ACE2, ASGR1 and KREMEN1 in normal human lung samples (Bar = 100um). **f**, Human lung organoids were infected with (right) or without (left) rVSV-GFP/SARS-CoV-2 S chimeric virions (SARS-CoV-2/GFP). GFP^+ cells were measured by flow cytometry 24hr post infection. Data in a-d are present as mean ± SEM, unpaired two-tailed Student's *t*-tests, **P* < 0.05, ***P*<0.01, ****P* < 0.001.